Compare Amphastar Pharmaceuticals Inc (AMPH) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.3. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | XDTE | |
|---|---|---|
Market Cap | $863.95M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $30.81 | $44.76 |
52-Week Low | $16.87 | $36.00 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
